Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.079

Full Text:

Abstract

Objective: to assess the expenditure of financial resources allocated for drug provision to the rheumatology department of the state clinical hospital.

Material and methods. The materials of the study are statistical reporting data on the expenditure of financial resources for the purchase of drugs for the Rheumatologic Department of Semashko Republican Clinical Hospital (Simferopol) for the period from June 2018 to May 2020. Based on the obtained results, a pharmacoeconomic assessment of the budgetary funds expenditure was carried out using ABC/VEN analysis.

Results. The total expenditure on the procurement of drugs for rheumatology department was 5,308,775.23 rubles. The list of medicines for the department included 50 items. The ABC analyses revealed that 80% of the budgetary funds (A class) were spent on 4 drugs included in the standards of pharmacotherapy for rheumatic diseases. According to VEN analysis all of them were classified as V category (vitally important).

Conclusion. The results revealed a high efficiency of the implementation of the state program of drug provision to the Rheumatologic Department of Semashko Republican Clinical Hospital. 

About the Authors

L. N. Sheikhmambetova
Georgievsky Medical Academy, Vernadsky Crimean Federal University
Russian Federation

Lilia N. Sheikhmambetova – Assistant Professor, Chair of Pharmacy 

5/7 Lenin Blvd., Republic of Crimea, Simferopol 295051, Russia



E. A. Egorova
Georgievsky Medical Academy, Vernadsky Crimean Federal University
Russian Federation

Elena A. Egorova – PhD (Pharm.), Associate Professor, Chair of Basic and Clinical Pharmacology

Scopus Author ID: 57204732581; RSCI SPIN-code: 6856-7328 

5/7 Lenin Blvd., Republic of Crimea, Simferopol 295051, Russia



K. N. Onishchenko
Georgievsky Medical Academy, Vernadsky Crimean Federal University
Russian Federation

Konstantin N. Onishchenko – Dr. Econ. Sc., Professor, Chair of Pharmacy

RSCI SPIN-code: 1847-1370

5/7 Lenin Blvd., Republic of Crimea, Simferopol 295051, Russia



E. I. Konyaeva
Georgievsky Medical Academy, Vernadsky Crimean Federal University
Russian Federation

Elena I. Konyaeva – MD, PhD, Associate Professor, Chair of Basic and Clinical Pharmacology 

RSCI SPIN-code: 6012-3431

5/7 Lenin Blvd., Republic of Crimea, Simferopol 295051, Russia



References

1. Chichasova N.V. Treatment of chronic joint diseases. Modern Rheumatology Journal. 2012; 6 (2): 89–98 (in Russ.). https://doi.org/10.14412/1996-7012-2012-734.

2. Branco J.C., Rodrigues A.M., Gouveia N., et al. EpiReumaPt study group. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt – a national health survey. RMD Open. 2016; 2 (1): e000166. https://doi.org/10.1136/rmdopen-2015-000166.

3. Salaffi F., Di Carlo M., Carotti M., et al. The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Biomed. 2019; 89 (4): 541–57. https://doi.org/10.23750/abm.v89i4.7298.

4. Federal State Statistics Service. Healthcare in Russia – 2019]. Available at: http://gks.ru/bgd/regl/b19_34/Main.htm (in Russ.) (accessed 17.05.2021).

5. Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018; 46 (1): 32–9 (in Russ.). https://doi.org/10.18786/2072-0505-2018-46-1-32-39.

6. Kolbin A.S., Kurylev A.A., Proskurin M.A., Balykina Yu.E. Health economic assessment of antirheumatic drugs in patients with reumathoid arthritis progressed after metotrexate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2016; 9 (3): 20–8 (in Russ.). https://doi.org/10.17749/2070-4909.2016.9.3.020-028.

7. Zyryanov S.K., Cheberda A.E., Belousov D.Yu. Pharmacoeconomic analysis of Actemra® in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy. Kachestvennaya klinicheskaya praktika / Good Clinical Practice. 2016; 3: 22–34 (in Russ.).

8. Minisola G. Rheumatic diseases and work ability. G Ital Med Lav Ergon. 2014; 36 (4): 276–81 (in Spanish).

9. van Vilsteren M., Boot C.R., Knol D.L., et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015; 16: 107. https://doi.org/10.1186/s12891-015-0562-x.

10. Smolen J.S., Landewé R., Bijlsna J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76 (6): 960–77. https://doi.org/10.1136/annrheumdis-2016-210715.

11. Nasonov E.L., Karateev D.E., Chichasova N.V. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Rheumatology Science and Practice. 2013; 51 (6): 609–22 (in Russ.).

12. Knevel R., Schoels M., Huizinga T.W., et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010; 69 (6): 987–94. https://doi.org/10.1136/ard.2009.126748.

13. Order of the Ministry of Health of the Russian Federation of December 24, 2012 No. 1470n “On approval of the standard of primary health care for rheumatoid arthritis”. Available at: http://www.consultant.ru/document/cons_doc_LAW_145349/ (in Russ.) (accessed 17.05.2021).

14. Belousov Yu.B. (Ed.) Medical technology assessment. Moscow; 2013 (in Russ.).

15. Pavlishchuk S.A., Labintseva N.V., Shulzhenko L.V., Zaburdyaeva Y.G. The ABC/VEN-analysis of drug provision in a pneumology department of a multi-disciplinary hospital. Pulmonologiya. 2013; 2: 85–8 (in Russ.). https://doi.org/10.18093/0869-0189-2013-0-2-85-88.

16. Order of the Ministry of Health of the Russian Federation of October 22, 2003 No. 494 “On the performance of the activities of doctors – clinical pharmacologists”. Available at: https://base.garant.ru/12133140/ (in Russ.) (accessed 17.05.2021).

17. Aronov L.S., Bogacheva N.S., Ivzhic M.A. Оptimizing drug supply system in a municipal hospital with the help of ABC and VEN analysis. Medical Technologies. Assessment and Choice. 2012; 1: 68–72 (in Russ.).


For citation:


Sheikhmambetova L.N., Egorova E.A., Onishchenko K.N., Konyaeva E.I. Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):334-341. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.079

Views: 86


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)